Dr Stewart Hay, CEO | www.therapeuticinnovation.com.au | (03) 9670 7018www.therapeuticinnovation.com.au.

Slides:



Advertisements
Similar presentations
Cancer Research UK strategy and funding Simon Vincent.
Advertisements

¨ Dr Alain Garcia General Secretary of the Rare Diseases National Plan The second National Plan for Rare Diseases in France
Eli Lilly and Company – Tailored Therapeutics and Diagnostics © Eli Lilly and Company 2012 The views and opinions expressed herein and/or during the accompanying.
The Early Phase (0-I-II) Clinical Drug Research Unit of Maastricht University Medical Center (MUMC) prof dr L. Van Bortel Drug Research Unit Maastricht.
Pharmacy Australia Centre of Excellence - (PACE).
Financial Conflicts of Interest in Medical Research Karen Santoro Deputy Ethics Counselor National Institute of Allergy and Infectious Diseases.
SGC OxfordSGC TorontoSGC Stockholm How Canada might develop its drug discovery sector.
1 Pharmaceutical Challenges for the Semantic Web.
Data-intensive Research Policy In Ireland A brief overview By J.-C. Desplat.
Brian C. Springer, MHA Executive Director Siteman Cancer Center Barnes-Jewish Hospital & Washington U. School of Med CCSG-CTSA Interactions Michael Bertram,
Genomics Commercialization Glen Schuler Managing Director, Industry Liaison Office University of Saskatchewan.
Cancer Nanotechnology: New Opportunities for Targeted Therapies FDA Public Meeting October 10, 2006 Piotr Grodzinski, Ph.D. Director, Nanotechnology for.
Discovery of new medicines through new models of collaboration Simon Ward Professor of Medicinal Chemistry & Director of Translational Drug Discovery Group.
1 The UK Opportunity: what is experimental medicine? UNLOCK YOUR GLOBAL BUSINESS POTENTIAL Pre- clinical develop- ment Phase I Phase II Phase III Product.
Ira S. Goodman Associate Director for Administration 2015 CCAF Meeting Lexington Kentucky UC San Diego Health System/ Moores Cancer Center Synergies 1.
Improving Animal and Human Health by Accelerating Veterinary Centered Entrepreneurship.
U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES National Institutes of Health National Institute of Neurological Disorders and Stroke U.S. DEPARTMENT OF HEALTH.
PhenX-Sickle Cell Disease Project at the National Heart, Lung, and Blood Institute/NIH Ellen M. Werner, Ph.D. Program Director Blood Epidemiology and Clinical.
Innovation Pathway AHSN Stakeholder Event Russ Watkins Assistant Director – Business Innovation & Improvement Newcastle Hospitals.
NCI Review of the Clinical Trials Process 6 th Annual National Forum on Biomedical Imaging in Oncology James H. Doroshow M.D. April 7, 2005 Bethesda, Maryland.
Bernard A Fox, PhD Immediate Past President and Chair, Executive Council Society for Immunotherapy of Cancer (SITC) Defining the Critical Hurdles in Cancer.
Dr. José M. Millán, PhD Deputy Director of CIBERER Universitary Hospital La Fe, Valencia, Spain Barriers and Challenges in Rare Diseases Research Centre.
Turning TypeOne to The Plan for a World without T1D JDRF Translational Development: Partnering for Success.
SARC Developmental Therapeutics Committee Update Chand Khanna Open Science: Biology to Therapy” SARC Developmental Therapeutics Committee Update Chand.
Progress in the RNOH-IOMS Joint Academic Strategy David Marsh Professor of Clinical Orthopaedics, Institute of Orthopaedics and Musculoskeletal Science.
OpenSpecimen User Meeting 9 Dec 2014 NIHR Leicester Cardiovascular BRU, OpenSpecimen and open source Nick Holden, Systems and Database Architect, LCBRU.
Activities at Academic Research Centers: Identifying Present Activities and Future Opportunities ICORD V February 24, 2009 Jim Cloyd, PharmD Lawrence Weaver.
Jordan Food & Drug Administration. Pharmaceutical Policy Studies Workshop RUD Unit Plan for RUD Unit.
Metals in Medicine Consortium Sydney Cancer Centre.
Developing medicines for the future and why it is challenging Angela Milne.
The FDA: Basic Facts It takes 12 to 15 years to develop a single drug Only 1 in 10,000 potential medications makes it completely through the process Only.
Australian Injury & Disability Insurance Network AIIN Health Special Interest Group & ICT Geelong November
The ERA-NET TRANSCAN-2, in continuity with the preceding ERA-NET TRANSCAN, aims at linking translational cancer research funding programmes in 15 Member.
The Australian Research Landscape 14 October 2015 Presented by Dr Fiona Cameron Executive Director Australian Research Council.
Human Embryos and Gene-editing Research and regulation in China Prof. Zhihong Xu, Peking University & Chinese Academy of Sciences.
Achieving FDA approval for novel new nanomaterials Table 5 Eva M. Sevick, discussion leader Johnny Chen Amos Gaikwad Wah Chiu.
Agency for Healthcare Research and Quality Advancing Excellence in Health Care The “Centers for Education & Research on Therapeutics” (CERTs)
Lunch & Learn Health Outcomes Research Dr Padma Kaul 31 October 2014.
CTEP Visiting Physician Externship Coordinator: Igor Espinoza-Delgado, M.D. NCI CTEP Investigational Drug Branch
Industry, Engagement and Innovation Presentation to the Universities Australia Conference 12 March 2015 Professor Aidan Byrne CEO, Australian Research.
ARCH – Applied Research for Connected Health An Enterprise Ireland and IDA Ireland Technology Centre Overview May 2016.
NSW Government Agencies Supporting Clinical Trials Strategic Planning, Policy Advice & Funding for Medical Research Economic Development & Support for.
From the Valley of Death to the Bridge of Life: Models for De-Risking Early Translational Projects from Around the World.
Healthcare Genetics in the NHS Landscape 1 st Gengage Network Conference June 2009 Dr Mike Winter Medical Director National Services Division.
Female Contraception- Pipeline Review, H Phone No.: +1 (214) id:
Translational Research: Case of Istanbul University
Copyright © 2007 American Medical Association. All rights reserved.
Professor Bryan Williams Chair of Medicine UCL
South Australian Life Science Initiatives
Gestora brasileiro focada exclusivamente na área da saúde.
Clinical research in Southampton is a partnership between University Hospital Southampton (UHS) NHS Foundation Trust and the University of Southampton.
The NIHR Southampton Clinical Research Facility was established by the Wellcome Trust and the Department of Health in The NIHR Southampton Clinical.
Non For Profit Model for Rare Disease Therapy Development
Research for all Sharing good practice in research management
Title Clinical research in Southampton is a partnership between University Hospital Southampton (UHS) NHS Foundation Trust and the University of Southampton.
Medical Research Funding and Regulation Third Annual Medical Research Summit March 6, 2003 Mary S. McCabe National Institutes of Health.
What is CICATS? The University of Connecticut, in partnership with regional hospitals, state agencies, and community health care organizations, has.
Clinical and Translational Science Awards Program
Suzanne M. Sensabaugh, MS, MBA
An Introduction to the NIHR programmes
Secondary Use of EHR: UK Experience 11 October 2007
CBTTC Fiscal Year 18 Strategic Objectives
Title Clinical research in Southampton is a partnership between University Hospital Southampton (UHS) NHS Foundation Trust and the University of Southampton.
Clinical research in Southampton is a partnership between University Hospital Southampton (UHS) NHS Foundation Trust and the University of Southampton.
Trial Funding and Engagement: The NIH Sponsored CTSA Program
BDHP Cancer Theme Seminar Haematology Cancers
Clinical research in Southampton is a partnership between University Hospital Southampton (UHS) NHS Foundation Trust and the University of Southampton.
Title Southampton Clinical Research Facility Southampton Biomedical Research Centre Clinical research in Southampton is a partnership between University.
Clinical research in Southampton is a partnership between University Hospital Southampton NHS Foundation Trust and the University of Southampton, combining.
The NIHR Southampton Clinical Research Facility was established by the Wellcome Trust and the Department of Health in The NIHR Southampton Clinical.
Presentation transcript:

Dr Stewart Hay, CEO | | (03) www.therapeuticinnovation.com.au

“Facilitated Therapeutic Product Development Pathways” Capabilities Suite of capabilities enabling development of novel health technologies from the laboratory bench into clinical trials 34 centres nationally: Drug discovery, Protein Production, Cell Therapies, Preclinical Testing, Clinical Trials, etc. 6 National Advisory Committees Funding Running $100M in research infrastructure projects. Supporting the Australian Government in ‘Translating Health Discovery into Clinical Application’ Previously funded research lead to 26 Phase I/II clinical trials Institutional Platform Investments into18 hospitals, 11 research institutes & 9 universities Engagement with the pharmaceutical industry, government agencies and comparable international organisations

The Aggregation Strategy

Feedback: Privacy Policy Feedback
Do Not Sell My Personal Information
About project: SlidePlayer Terms of Service

© 2025 SlidePlayer.com. Inc. All rights reserved.